HR Positive/ HER2 Negative Breast Cancer Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

- Breast Cancer total incident population in the 7MM is expected to grow at CAGR of 0.83%, during the study period [2017–2028].

- The United States shows higher Breast Cancer incidence in the United States with 266,120 cases in 2017.

- Among the EU-5 countries, Germany ranked first with 71,585 cases in 2017, followed by Italy, and France, in 2017, whereas Breast Cancer incident population in Japan was found to be 89,100.

LAS VEGAS, Sept. 10, 2019 /PRNewswire/ -- DelveInsight launched Hormone Receptor positive/ Human Epidermal Receptor 2 negative Breast Cancer Market Insights, Epidemiology and Market Forecast- 2028

1. HR+/ HER2- Breast Cancer market report covers a detailed overview and comprehensive insight of the HR+ / HER2- breast cancer Epidemiology and HR+/ HER2- breast cancer market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. HR positive/ HER2 negative breast cancer market report provides insights into the current and emerging HR positive/ HER2 negative breast cancer therapies.
3. HR positive/ HER2 negative breast cancer market report offers a global historical and forecasted market covering drug outreach in 7 MM.
4. HR positive/ HER2 negative breast cancer market report provides an edge that will help in developing business strategies, by understanding trends shaping and driving the Human Epidermal Receptor 2 negative Breast Cancer market.

"Among the 7MM countries, the United States had the highest HER2 negative breast cancer market size in 2017 that accounts for approximately 83.96% of the total market."

Get a free sample page: https://bit.ly/2lLQViM

At present, the growth of HR positive breast cancer market size is attributed to drugs that have been approved for Hormone Receptor positive breast cancer by the US FDA

Among the EU-5 countries, Germany had the highest HR-positive/HER2-negative breast cancer market size in 2017, which accounts for approximately 25.51% of the total market. Of the therapies prescribed as first-line breast cancer treatment, CDK4/6 inhibitors occupy the largest market share, of which Ibrance contributed the majority of the share, followed by Kisqali and Verzenio. The second position in the first-line treatment options is occupied by SERD class (Faslodex). Among the second and higher lines of therapy, CDK4/6 inhibitors occupy the largest breast cancer market share. 

As the HR positive breast cancer mostly affects women. The treatment management of this specific cancer is complex and patient-centric, as treatment and outcomes differ significantly according to biomarker status among other patient characteristics, indicating a trend towards higher personalized medicine based upon patient biomarkers and physiologic characteristics.

Current treatment landscape is well-provided with treatment management. However, there is a lack of treatment and diagnostic guidelines specific to the ER-Positive breast cancer required for the management and diagnosis of ER-positive breast cancer. In recent years, there are many advancements in early detection, prevention, risk stratification, and therapeutic strategies, as well as supportive care for patients with breast cancer, and these have resulted in essential improvements in morbidity and mortality. There is a myriad of companies that are developing drugs for breast cancer treatment.

The expected launch of breast cancer emerging therapies is believed to create a positive impact on the HR positive/ HER2 negative breast cancer market size in the upcoming years. 

1. SHR6390
2. TESETAXEL
3. RAD1901
4. IMMU-132
5. RG7440
6. Entinostat
7. MK-3475
8. EGL-5385-C-1701
9. MM-121
10. GSK525762 (Molibresib)
11. SAPANISERTIB (TAK-228)
12. Radium-223 dichloride
    and many others

Some of the HR positive/ HER2 negative breast cancer companies are:-

1. Jiangsu HengRui Medicine Co.
2. Odonate Therapeutics
3. Radius Pharmaceuticals
4. Immunomedics
5. Roche Group
6. Syndax Pharmaceuticals
7. Merck Sharp & Dohme Corp
8. Eagle Pharmaceuticals 
9. Merrimack Pharmaceuticals
10. GlaxoSmithKline
11. Millennium Pharmaceuticals
12. Bayer
    and many others 

Get a free demo of the report: https://bit.ly/2lLQViM

Table of contents

1. Key Insights

2. Hormone Receptor positive Breast Cancer Market Overview at a Glance

3. Human Epidermal Receptor 2 negative breast cancer Disease Background and Overview

4. HR 2 positive Epidemiology and Patient Population

5. Hormone Receptor of Positive Breast Cancer Country Wise-Epidemiology 

5.1. United States

5.2. EU5 Countries

5.3. Germany

5.4. France

5.5. Italy

5.6. Spain

5.7. United Kingdom

5.8. Japan

6. Estrogen-Receptor Positive Breast Cancer Treatment 

7. HER 2 negative Marketed Products

7.1. Ibrance (Palbociclib): Pfizer

7.2. PIQRAY (Alpelisib; BYL719): Novartis

7.3. Lynparza (olaparib): AstraZeneca Pharmaceuticals

7.4. Verzenio (Abemaciclib): Eli Lilly

7.5. Kisqali (Ribociclib; LEE011): Novartis Pharmaceuticals

7.6. Afinitor (Everolimus): Novartis

7.7. Faslodex (Fulvestrant) Injection: AstraZeneca

7.8. Arimidex (Anastrozole): AstraZeneca

7.9. Aromasin (Exemestane): Pharmacia and Upjohn Company

7.10. Femara (Letrozole): Novartis Pharmaceuticals

8. Unmet Needs

9. HR positive/ HER2 negative breast cancer breast cancer Emerging Drugs

9.1. Key Cross Competition

9.2. SHR6390: Jiangsu HengRui Medicine Co.

9.3. TESETAXEL: Odonate Therapeutics

9.4. RAD1901: Radius Pharmaceuticals

9.5. IMMU-132 (Sacituzumab Govitecan): Immunomedics

9.6. Ipatasertib (RG7440): Roche Group

9.7. Venclexta: Roche Group

9.8. Entinostat: Syndax Pharmaceuticals

9.9. Pembrolizumab (MK-3475): Merck Sharp and Dohme

9.10. Eribulin Mesylate: Merck Sharp & Dohme Corp.

9.11. MM-121: Merrimack Pharmaceuticals

9.12. GSK525762 (Molibresib): GlaxoSmithKline

9.13. SAPANISERTIB (TAK-228): Millennium Pharmaceuticals

9.14. Radium-223 dichloride: Bayer

9.15. EGL-5385-C-1701(fulvestrant): Eagle Pharmaceuticals

10. HR+/HER2- Post Menopause Breast Cancer Market Analysis (7MM)

11. The United States HR positive/ HER2 negative breast cancer Market Analysis

11.1. The United States HR positive/ HER2 negative breast cancer Market Outlook

11.2. United States HR positive/ HER2 negative breast cancer Market Size

12. EU-5 HR positive/ HER2 negative breast cancer Market Analysis

12.1. EU-5 HR positive/ HER2 negative breast cancer Market Outlook

12.2. Germany HR positive/ HER2 negative breast cancer Market Size

12.3. France HR positive/ HER2 negative breast cancer Market Size

12.4. Italy HR positive/ HER2 negative breast cancer Market Size

12.5. Spain HR positive/ HER2 negative breast cancer Market Size

12.6. The United Kingdom HR positive/ HER2 negative breast cancer Market Size

13. Japan Market Outlook

14. Market Drivers

15. Market Barriers

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Related reports: 

• Triple Negative Breast Cancer (TNBC) Market Insight, Epidemiology and Market Forecast - 2027

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Triple Negative Breast Cancer market size from 2016 to 2027 segmented by G8 markets. The Report also covers current treatment practise/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

• HER2 -Negative Metastatic Breast Cancer Market Insights, Epidemiology and Market Forecast-2028

The report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017-2028.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330